When Duncan Bagshaw was appointed King’s Counsel, it marked a significant milestone in his legal career.

Health Canada has made important changes to how it authorizes biosimilar drugs for sale in Canada. Notably, clinical efficacy studies (i.e., phase 3 studies) comparing the efficacy of the biosimilar candidate drug to the innovative drug it copies “are not typically required.”

A requirement in a company’s by-laws for shareholders to resolve disputes through private arbitration is known as a “mandatory arbitration” clause.

The Taiwanese Government planned in 2017 to have an energy mix comprised of 50 per cent natural gas, 27 per cent coal, 20 per cent renewable energy, 2 per cent other energy and 1 per cent nuclear energy by 2025.

Global law firm Norton Rose Fulbright has secured a decisive victory for SRAM before the Brussels Court of Appeal (Markets Court), which dismissed the Union Cycliste Internationale’s (UCI) appeal in full and upheld the Belgian Competition Authority’s (BCA) decision of October 2025 suspending the Maximum Gear Ratio Test Protocol (Protocol).

Effective October 20, 2026, federally regulated employers will be required to review and possibly raise wage rates for some employees under new “Equal Treatment” wage rules.

Join Norton Rose Fulbright for a training session on key legal and regulatory issues for firms seeking to trade on prediction markets.

Amanda Town and Richard Whish KC (Hon) discuss a new investigation announced by the Competition and Markets Authority (CMA) on 2 March 2026 into suspected anti-competitive conduct in the hotels sector.

Following significant reforms to the UK competition regime only last year under the Digital Markets, Competition and Consumers Act 2024, the UK Government is now planning further, targeted legislative reforms linked to its economic growth mission, also building on growth-related reforms regarding the Competition and Markets Authority’s (CMA) policy and procedure over the past year.

The Court of Appeal of the Unified Patent Court (UPC) has, for the first time, referred several fundamental questions to the Court of Justice of the European Union (CJEU) concerning the international jurisdiction of the UPC and the patent law liability of so called product compliance authorised representatives.

Whistleblowing can take many different forms, can encompass a wide range of different concerns and can vary in terms of seriousness.

Lawdragon honored 44 Norton Rose Fulbright lawyers in the fifth edition of its Lawdragon 500 Leading Global Litigators guide.

The Government of Canada recently introduced significant updates to its export control framework through proposed amendments to the Export Control List (ECL), with further guidance available in the updated Guide to Canada’s Export Control List (Guide).

Norton Rose Fulbright is supporting mHUB’s Energy Tech Accelerator, a program designed to advance startups developing technologies at the intersection of compute and energy.

TPR reports mixed evidence on DC consolidation, with scale lowering costs but not reliably improving investment outcomes.

TPR puts pressure on DB schemes to address value data gaps ahead of dashboards, with public launch now expected in 2027 to 2028.

TPR’s supports AI in pensions, setting expectations on governance, data and innovation. Guidance on responsible adoption to follow.

TPR consults on its five-year strategy, with a new focus on the whole retirement journey.

A cross-border team from Norton Rose Fulbright represented Optimi Health Corp., a commercial-stage psychedelics pharmaceutical company, on its upsized and oversubscribed US$15 million initial public offering and concurrent listing on the Nasdaq Capital Market.

Strong DB funding sees TPR encourage schemes to focus on endgame planning and long-term strategy.